It has exhibited considerable therapeutic efficacy in patients with RET fusion-positive metastatic NSCLC, RET mutant MTC, and RET fusion-positive thyroid, with no significant off-target toxicity [154,169]. This evidence concerns the gene RET and non-small cell lung carcinoma.